ETON · Eton Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| BRYNJELSEN SEAN Chief Executive Officer | ▼ Sell | Open Market | 961,194 Shares held | 8/20/2026 | View profile |
| Gruber James R. Chief Financial Officer | ▼ Sell | Tax Withholding | 213,420 Shares held | 1/14/2026 | View profile |
| Norbert G. Riedel Director | ▲ Buy | Option Exercise | 67,155 Shares held | 4/21/2026 | View profile |
| MAIER PAUL V Director | ▼ Sell | Open Market | 59,745 Shares held | 8/28/2026 | View profile |
| Opaleye Management Inc. 10% Owner | ▼ Sell | Open Market | 40,000 Shares held | 7/14/2026 | View profile |
| Krempa David Chief Business Officer | ▼ Sell | Open Market | 37,025 Shares held | 8/24/2026 | View profile |
| Erdogan-Trinkaus Ipek Chief Commercial Officer | ▼ Sell | Tax Withholding | 2,403 Shares held | 12/12/2025 | View profile |
| Adams Jennifer McKie Director | ▼ Sell | Open Market | 0 Shares held | 6/17/2026 | View profile |
Transaction History
| MAIER PAUL V | ▲ Buy | Option Exercise | 50,000 | $189K | 8/28/2026 |
| MAIER PAUL V | ▼ Sell | Open Market | 36,387 | $2.1M | 8/28/2026 |
| MAIER PAUL V | ▼ Sell | Open Market | 13,485 | $812K | 8/28/2026 |
| MAIER PAUL V | ▼ Sell | Open Market | 128 | $8K | 8/28/2026 |
| Krempa David | ▲ Buy | Option Exercise | 25,000 | $183K | 8/24/2026 |
| Krempa David | ▼ Sell | Open Market | 25,000 | $1.6M | 8/24/2026 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 47,307 | $2.8M | 8/20/2026 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 36,373 | $2.2M | 8/20/2026 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 7,342 | $456K | 8/20/2026 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 8,978 | $562K | 8/19/2026 |
| BRYNJELSEN SEAN | ▲ Buy | Option Exercise | 200,000 | $274K | 7/14/2026 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 15,000 | $563K | 7/14/2026 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 13,315 | $500K | 7/14/2026 |
| Krempa David | ▲ Buy | Option Exercise | 10,000 | — | 7/12/2026 |
| BRYNJELSEN SEAN | ▲ Buy | Option Exercise | 27,500 | — | 7/12/2026 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 6,685 | $257K | 7/7/2026 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 20,000 | $767K | 7/7/2026 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 10,000 | $380K | 7/6/2026 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 25,000 | $935K | 7/2/2026 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 65,000 | $2.4M | 7/2/2026 |
| Adams Jennifer McKie | ▲ Buy | Option Exercise | 50,000 | $189K | 6/17/2026 |
| Adams Jennifer McKie | ▼ Sell | Open Market | 50,000 | $1.6M | 6/17/2026 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 119,852 | $3.8M | 5/28/2026 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 148 | $5K | 5/28/2026 |
| Krempa David | ▲ Buy | Option Exercise | 12,476 | $17K | 5/27/2026 |
| Krempa David | ▲ Buy | Option Exercise | 7,203 | $26K | 5/27/2026 |
| Krempa David | ▼ Sell | Open Market | 19,679 | $619K | 5/27/2026 |
| Krempa David | ▲ Buy | Option Exercise | 25,000 | $35K | 5/26/2026 |
| Krempa David | ▲ Buy | Option Exercise | 12,524 | $17K | 5/26/2026 |
| Krempa David | ▼ Sell | Open Market | 37,524 | $1.2M | 5/26/2026 |
| Krempa David | ▲ Buy | Option Exercise | 30,591 | $110K | 5/22/2026 |
| Krempa David | ▼ Sell | Open Market | 32,963 | $1.1M | 5/22/2026 |
| Krempa David | ▼ Sell | Open Market | 9,315 | $316K | 5/22/2026 |
| Krempa David | ▼ Sell | Open Market | 519 | $18K | 5/22/2026 |
| Norbert G. Riedel | ▲ Buy | Option Exercise | 12,500 | $91K | 4/21/2026 |
| Norbert G. Riedel | ▲ Buy | Option Exercise | 19,655 | $169K | 4/21/2026 |
| Norbert G. Riedel | ▼ Sell | Other | 30,000 | $133K | 2/3/2026 |
| Krempa David | ▼ Sell | Tax Withholding | 1,942 | $30K | 1/14/2026 |
| Gruber James R. | ▼ Sell | Tax Withholding | 2,293 | $35K | 1/14/2026 |
| BRYNJELSEN SEAN | ▼ Sell | Tax Withholding | 5,015 | $77K | 1/1/2026 |
| Erdogan-Trinkaus Ipek | ▼ Sell | Tax Withholding | 85 | $1K | 12/12/2025 |
| Krempa David | ▼ Sell | Tax Withholding | 6,264 | $106K | 12/12/2025 |
| Gruber James R. | ▼ Sell | Tax Withholding | 4,542 | $77K | 12/12/2025 |
| BRYNJELSEN SEAN | ▼ Sell | Tax Withholding | 6,732 | $113K | 12/12/2025 |
| Gruber James R. | ▼ Sell | Open Market | 2,631 | $42K | 8/20/2025 |
| Gruber James R. | ▼ Sell | Open Market | 39,082 | $632K | 8/19/2025 |
| Krempa David | ▼ Sell | Open Market | 10,223 | $151K | 6/16/2025 |
| Krempa David | ▼ Sell | Open Market | 6,800 | $100K | 6/13/2025 |
| Krempa David | ▼ Sell | Open Market | 16,977 | $253K | 6/12/2025 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 2,930 | $46K | 6/10/2025 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 5,000 | $79K | 6/10/2025 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 70,000 | $1.2M | 6/5/2025 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 70,000 | $1.2M | 6/4/2025 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 60,945 | $1.1M | 6/3/2025 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 8,655 | $159K | 6/3/2025 |
| BRYNJELSEN SEAN | ▼ Sell | Open Market | 400 | $8K | 6/3/2025 |
| Norbert G. Riedel | ▲ Buy | Option Exercise | 27,400 | $98K | 1/3/2025 |
| Norbert G. Riedel | ▲ Buy | Option Exercise | 50,000 | $189K | 1/3/2025 |
| Norbert G. Riedel | ▲ Buy | Option Exercise | 25,000 | $87K | 1/3/2025 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 10,000 | $80K | 10/23/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 30,000 | $211K | 10/8/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 3,970 | $28K | 10/8/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 10,000 | $72K | 10/7/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 1,248 | $9K | 10/7/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 15,000 | $102K | 10/4/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 1,852 | $13K | 10/4/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 45,000 | $214K | 9/11/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 5,000 | $24K | 9/11/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 50,000 | $233K | 9/10/2024 |
| Opaleye Management Inc. | ▲ Buy | Open Market | 7,500 | $35K | 9/10/2024 |
| BRYNJELSEN SEAN | ▲ Buy | Open Market | 10,000 | $21K | 9/22/2022 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 25,000 | $117K | 11/17/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 11,500 | $56K | 11/16/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 938 | $5K | 11/16/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 2,500 | $12K | 11/15/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 500 | $2K | 11/15/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 50,000 | $305K | 11/8/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 2,661 | $16K | 11/8/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 159,300 | $1.0M | 11/5/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 8,401 | $53K | 11/5/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 81,700 | $526K | 11/4/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 4,000 | $26K | 11/4/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 110,000 | $718K | 11/3/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 6,500 | $42K | 11/3/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 82,500 | $417K | 10/12/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 4,807 | $24K | 10/12/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 32,500 | $163K | 10/11/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 1,601 | $8K | 10/11/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 41,000 | $205K | 10/8/2021 |
| Opaleye Management Inc. | ▼ Sell | Open Market | 2,692 | $13K | 10/8/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Eton Secures U.S. License for LIBERVANT Buccal Film
Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.
Eton Secures U.S. License for LIBERVANT Buccal Film. Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.